

Colorado HB 19-1131 Disclosure

Cystaran® (Cysteamine)

Leadiant Biosciences, Inc. (“Leadiant”) provides the following information to Colorado prescribers, as required by Colorado House Bill 19-1131.

The pricing information below reflects Leadiant’s Wholesale Acquisition Costs (“WAC”) for the Leadiant product. The WAC represents published catalogue or list price and may not represent actual transactional prices.

The price a customer pays may vary from the prices listed, depending, for example, on how the customer purchases the product, the availability of discounts, the wholesaler/distributor, or other charges.

WAC for Cystaran®

PRODUCT	NDC	DOSAGE FORM AND STRENGTH	WHOLESALE ACQUISITION COST (WAC)
Cystaran®	54482-0035-02	Ophthalmic Solution 0.44 %	\$2,953.83

The list below provides the names of generic prescription drugs in the same Therapeutic Class as the Leadiant product. Note that the drugs listed are not necessarily the generic form of **Cystaran®**. Rather, these drugs could be a generic form listed in the same Therapeutic Class as **Cystaran®**.

This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information.

Generic Prescription Drugs in the Same Therapeutic Class*

PRODUCT	NDC	DOSAGE FORM AND STRENGTH	WHOLESALE ACQUISITION COST (WAC)
Cystadrops	55292-0410-05	Ophthalmic Solution 0.37 %	\$2,654.99

* Source: Generic Prescription Drug Data Extracted from Medi-Span

For purposes of listing the generic prescription drugs above, the Therapeutic Class is derived from “Macular Degeneration Agents”

The trademarks or service marks herein are owned by, licensed to, promoted by, or distributed by Leadiant, its subsidiaries or its affiliates.

Copyright © 2026 Leadiant All rights reserved.
10/12/2026